GLP-1 agonists have been shown to be beneficial in a lengthening list of diseases, but it seems Alzheimer’s disease may not be among them. Novo Nordisk has just released the topline findings from two eagerly anticipated phase 3 trials of its oral formulation of GLP-1 drug semaglutide, with the deeply disappointing news that the drug…
Prospects for Bayer’s oral Factor XIa inhibitor asundexian were looking speculative when it failed a phase 3 trial in atrial fibrillation (AF), but new data in secondary stroke prevention could get the programme back on track. The results of the OCEANIC-STROKE study reveal that asundexian was more effective than placebo when given on top of…
Hopes that anti-tau drugs could join those targeting amyloid as treatments for Alzheimer’s disease have been dented by the failure of a phase 2b trial of Johnson & Johnson’s posdinemab. The AuTonomy study of posdinemab had been designed as a proof-of-concept for the anti-tau antibody in early-stage Alzheimer’s patients, but the drug failed to show…
Brain computer interface (BCI) developer Paradromics has been cleared by the FDA to start a clinical trial of its Connexus implant that will test how well it can convert thoughts into speech. Austin, Texas-based Paradromics said the investigational device exemption (IDE) from the US regulator for the Connect-One study of Connexus is the first for…
Shares in Agios Pharma lost nearly half their value in pre-market trading today after it posted mixed clinical results from a phase 3 trial of its sickle cell disease (SCD) therapy mitapivat, sending its investors into a spin. In the pivotal RISE UP study, mitapivat – an orally-active pyruvate kinase (PKR) activator – was able…
Mumbai: Glenmark Specialty, a wholly owned subsidiary of Glenmark Pharma, said China’s National Medical Products Administration (NMPA) has approved Ryaltris, its nasal spray for the treatment of allergic rhinitis in adults and children. The commercialisation rights of the drug in China will be with Grand Pharmaceuticals under an exclusive licensing agreement. The details of the…
Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its clinical trials who was hospitalised for liver toxicity died. The company’s stock was down almost 29% at the time of writing after the news emerged, having already slumped on last month’s announcement that the phase 3 MAGNITUDE…
George Medicines’ recently-approved high blood pressure therapy Widaplik could offer a desperately needed new treatment for patients with intracerebral haemorrhage (ICH), the most severe form of stroke. An investigator-led study reported this week at the World Stroke Congress in Barcelona has shown that Widaplik (also known as GMRx2), a single-tablet combination comprising low doses of…
Obicetrapib Improves Lipid Profile and Reduces Cardiovascular Events, Suggests Study We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Eli Lilly has built the case for its oral GLP-1 agonist orforglipron with two more phase 3 readouts, including new data showing that it can improve blood glucose compared to a go-to therapy for type 2 diabetes. Topline results from the ACHIEVE-2 trial showed orforglipron at a dose of 12 mg was better than AstraZeneca’s…